Hoffmann-la Roche

This study tested several combinations of immunotherapy drugs in 341 people with metastatic pancreatic cancer that had spread. The goal was to see if these treatments could shrink tumors and control the disease. Participants were split into two groups: those who had not yet recei…

This study tested a new combination of drugs (tiragolumab plus atezolizumab and chemotherapy) against the current standard treatment (pembrolizumab plus chemotherapy) in 542 people with advanced non-squamous lung cancer who had not been treated before. The goal was to see if the …

This study tested several new drug combinations in 281 adults with chronic hepatitis B who were already on standard antiviral therapy. The goal was to see if these combinations could safely clear the hepatitis B surface antigen from the blood, which would indicate better disease …

This study looked at how well and how safely ocrelizumab works over a longer time for people with multiple sclerosis (MS). Over 1,000 participants who had already been in earlier Roche studies took part. Researchers tracked disability changes, relapse rates, and side effects to s…

This early-phase study tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to check safety and find the right dose. While the drug aims to control the cancer, it is not expected …

This study tested whether adding a new drug (tiragolumab) to a standard immunotherapy (atezolizumab) helps shrink tumors or slow cancer growth in people with advanced head and neck cancer that cannot be cured. 123 adults whose tumors had a specific marker (PD-L1 positive) and who…

This study tested whether adding two immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy helps people with advanced esophageal cancer that cannot be removed by surgery. About 460 participants received either the immunotherapy combo plus chemo or a placebo …

This study tested different drug combinations in 12 people with advanced head and neck cancer that had not been treated before. The goal was to see if these combinations could make the tumor disappear before surgery. The study was small and early-stage, so results are limited.

This study tested a new eye medication called faricimab against an existing treatment (ranibizumab) in 280 people with vision loss caused by severe nearsightedness. The goal was to see if faricimab could improve vision just as well as the current standard treatment. Participants …

This study tested whether adding a new drug called tiragolumab to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer without their cancer getting worse. About 490 adults who had not received prior treatment for this stage of canc…

This study tested a drug called alogabat in 48 children aged 5-17 with Angelman syndrome (a specific genetic type). The goal was to see how the drug moves through the body and if it is safe. Researchers also looked at brain activity changes to see if the drug works as expected. T…

This study tested whether adding the drug pertuzumab to standard chemotherapy and trastuzumab could help prevent breast cancer from returning after surgery. About 4,800 people with HER2-positive breast cancer took part. The results showed that the three-drug combination improved …

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye due to inflammation. The trial involved 256 adults with non-infectious uveitis and aimed to see if the drug improves vision…

This early-phase study tested a new drug combination for people with a fast-growing lymphoma (DLBCL) that returned after initial treatment. The study included 43 adults who were healthy enough for a stem cell transplant or CAR-T therapy. They received the experimental drug glofit…

This study tested a combination of two targeted drugs, venetoclax and obinutuzumab, against standard chemotherapy in 166 fit patients with untreated chronic lymphocytic leukemia (CLL) who lack certain genetic mutations. The goal was to see if the new combo could achieve deeper re…

This study tested a drug called TRO19622 in 22 adults with NASH, a type of fatty liver disease. Participants took the drug or a placebo for one month to see if it improved liver enzyme levels and was safe. The goal was to gather early information on whether the drug might help co…

This study tested whether a shot under the skin (subcutaneous) of the immunotherapy drug atezolizumab works as well as the standard IV drip for people with advanced non-small cell lung cancer. About 438 patients who had already tried chemotherapy took part. The goal was to see if…

This study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participant…

This study looked at how well the drug MIRCERA controls anemia in 144 adults with chronic kidney disease stages 3-4 who are not yet on dialysis. Researchers tracked hemoglobin levels and safety over 12 months in a real-world setting. The goal was to see if patients could maintain…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This study looked at the long-term safety of the drug tocilizumab (RoActemra/Actemra) in children with a type of arthritis called polyarticular-course juvenile idiopathic arthritis. Seven children who had already finished a main study received the drug every 4 weeks for up to 2 y…

This study tested a monthly injection called Mircera for people with chronic kidney disease who have anemia (low red blood cells) and are not yet on dialysis. 75 adults received the shot for 3 to 12 months. The goal was to see if it could safely raise and maintain hemoglobin leve…

This study tested the safety of combining the immunotherapy drug atezolizumab with the chemotherapy nab-paclitaxel in 184 people with advanced triple-negative breast cancer that had not been treated with chemotherapy before. The goal was to see how many patients experienced serio…

This study tested a new way to give two immunotherapy drugs (tiragolumab and atezolizumab) together as a single injection. It involved 64 people with advanced solid tumors that had spread or come back. The main goal was to check safety and how the drugs move through the body, not…

This study tested two experimental drugs (lomvastomig and tobemstomig) that target multiple immune checkpoints, compared to the standard immunotherapy nivolumab, in 190 people with advanced or metastatic esophageal squamous cell carcinoma. The goal was to see if these new drugs c…

This study followed 322 adults with moderate to severe rheumatoid arthritis who were starting treatment with tocilizumab (RoActemra/Actemra). Researchers tracked how well the drug controlled disease activity and monitored safety over 12 months in real-world clinics. The goal was …

This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment with CDK4/6 inhibitors. Participants received either a standard hormone therapy (fulvestran…

This study tested whether a combination of two immunotherapy drugs (atezolizumab and tiragolumab) works better than the standard drug durvalumab for people with stage 3 lung cancer that cannot be removed by surgery. Participants had already received chemotherapy and radiation and…

This study tested whether using a person's tumor genetic profile to choose treatment works better than standard chemotherapy for cancer of unknown primary (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either gene-guided therapy …

This study tested an experimental drug called vamikibart, given as an eye injection, for people with uveitic macular edema — swelling in the back of the eye caused by inflammation. 245 adults with this condition took part. The main goal was to see if the drug improves vision by a…

This study tested several immunotherapy drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery. Participants received either a combination of immunotherapy drugs or standard chemotherapy. The goa…

This study tested a combination of two drugs, atezolizumab and cabozantinib, against a standard chemotherapy (docetaxel) in 366 people with advanced non-small cell lung cancer that had worsened after previous treatments. The goal was to see if the combination helped people live l…

This study tested a small, refillable implant placed in the eye that continuously releases medication to control diabetic retinopathy, a complication of diabetes that can damage vision. 174 adults with moderate-to-severe diabetic retinopathy participated. The goal was to see if t…

This study tested whether a once-monthly injection of Mircera could keep hemoglobin levels stable in dialysis patients with anemia, compared to the standard epoetin alfa given more often. About 233 adults on dialysis took part. The goal was to see if the monthly shot was as safe …

This study tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with advanced triple-negative breast cancer that returned within a year of initial treatment. About 595 participants received either the drug combo or a placebo plus chemo. …

This study tested whether adding the drug polatuzumab vedotin to standard chemotherapy (R-CHP) works better than the usual treatment (R-CHOP) for people with untreated diffuse large B-cell lymphoma. About 1000 participants received either the new combination or the standard treat…

This study tested an investigational eye injection called RO7200220 (vamikibart) in 394 people with diabetic macular edema, a condition that causes vision loss due to swelling in the back of the eye. The goal was to see if it improves vision and reduces swelling compared to an ex…

This study tested whether adding a new drug (RO7200220) to a standard treatment (ranibizumab) works better than the standard treatment alone for people with diabetic macular edema, a condition that causes vision loss in people with diabetes. 187 participants received injections i…

This study tested a drug called crovalimab to see if it could prevent painful vaso-occlusive episodes (VOEs) in people with sickle cell disease. 95 participants received either crovalimab or a placebo alongside their usual treatments. The goal was to reduce the number of crises r…

This study compared a single dose of baloxavir marboxil to a 5-day course of oseltamivir in 100 Chinese children aged 1 to 12 with flu symptoms. The main goal was to check safety, including side effects. Researchers also measured how quickly symptoms like cough and fever improved…

This study looked at whether people with HER2-positive breast cancer prefer getting their medication at home or in the hospital. About 346 participants were randomly assigned to receive treatment in both settings and then asked which they liked more. The goal was to see if home t…

This study looked at whether people with non-small cell lung cancer prefer getting their medication as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 179 adults took part, including those with early-stage cancer after surgery and those wit…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study tested whether using a liquid biopsy (a blood test that looks for cancer DNA) early in the diagnosis process could speed up care for people with advanced lung or gastrointestinal cancer. Researchers compared the timing of diagnosis and treatment recommendations between…